Division of Biogen Inc.
Latest From Stromedix Inc.
The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.
Finance Watch: Surrozen Raises $33m In $483m February Flurry; Also, Are Reverse Mergers This Year's IPOs?
Surrozen raised $33m to fund drug development programs targeting Wnt ligands for various indications during a February VC financing flurry that occurred despite a drop in IPOs. Taking an alternative route to going public, some biopharma companies have completed reverse mergers in recent weeks and months.
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
Michael Gilman, PhD, CEO
Brad Maroni, MD, CMO
Shelia Violette, PhD, VP, Rsch.
- Contact Info
Phone: (617) 674-8400
One Canal Park, Ste. 1120
Cambridge, MA 02141
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.